Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hightower, Kendra E., Wang, Ruolan, DeAnda, Felix, Johns, Brian A., Weaver, Kurt, Shen, Yingnian, Tomberlin, Ginger H., Carter, H. Luke, Broderick, Timothy, Sigethy, Scott, Seki, Takahiro, Kobayashi, Masanori, Underwood, Mark R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2011
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3187001/
https://ncbi.nlm.nih.gov/pubmed/21807982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00157-11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados